The Asia Pacific Advanced Therapy Medicinal Products CDMO Market would witness market growth of 16.9% CAGR during the forecast period (2022-2028).
The market is expanding for two key reasons, an increase in cancer incidence and an increase in funding for R&D in oncology gene therapy activities. Additionally, supportive government regulations for treatment are expected to foster a number of opportunities that will propel the market throughout the course of the forecast year.
A new gene will incorporate into the genome of the patient and proceed to function without compromising with the functions of other genes, which lowers the risk of gene therapy developed for oncology. Advanced therapy medicinal products CDMO market has also been fueled by the continued development of products for sophisticated therapies. These market changes are a result of the increasing demand for products.
During the projection period, it is expected that increasing product demand will create rapid advancements in gene and cell therapies. Biopharmaceutical businesses have recently placed more emphasis on outsourcing manufacturing services to CDMOs. Outsourcing some of the production and development activities enables research organizations and drug developing companies to focus on core and relevant competencies.
The regional market participants would be able to expand their offers and secure the largest possible revenue share attributable to the expanding healthcare infrastructure and enhanced government initiatives. As disposable incomes expand in emerging economies and the region's healthcare infrastructure advances it would increase access to novel treatment options. Furthermore, the patient base are especially large in nations like Korea and India. Therefore, it is anticipated that throughout the forecast period, these factors would present new growth opportunities for the participants’ active in the advanced therapy medicinal products CDMO market.
The China market dominated the Asia Pacific Advanced Therapy Medicinal Products CDMO Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $695 million by 2028. The Japan market is estimated to grow a CAGR of 16.2% during (2022 - 2028). Additionally, The India market would experience a CAGR of 17.6% during (2022 - 2028).
Based on Indication, the market is segmented into Oncology, Cardiology, Central Nervous System & Musculoskeletal, Infectious Disease, Dermatology, Endocrine, Metabolic, Genetic, Immunology & Inflammation, Ophthalmology, Hematology, Gastroenterology, and Others. Based on Product, the market is segmented into Gene Therapy, Cell Therapy, and Tissue Engineered & Others. Based on Phase, the market is segmented into Phase I, Phase II, Phase III, and Phase IV. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Advanced Therapy Medicinal Products CDMO Market is Projected to reach USD 11.9 Billion by 2028, at a CAGR of 16.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc. (Patheon, Inc.), AGC Biologics, Inc. (AGC, Inc.), Catalent, Inc., Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation), WuXi AppTec Co., Ltd. (WuXi Advanced Therapies), Lonza Group AG, Celonic AG (JRS PHARMA GmbH & Co. KG), Rentschler Biopharma SE, and Bio Elpida (Polyplus-transfection SA.)
By Indication
By Product
By Phase
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 